Cellply is bringing to market an innovative, fully automated, walkaway analytical platform for profiling of immune cell function. The platform offers a dramatically improved understanding of cell function at the single cell level with applicability across all stages of R&D into clinical development and manufacturing for immune cell therapy and other immunotherapies.

The analytic platform allows to create 10’s of thousands of miniature co-cultures and characterize single immune cells through multiple assays run in parallel, as cytotoxicity, serial killing, cytokines, antigen expression and immunophenotypes.
The Co-Culture Array technology allows the observation of thousands of individual immune cells interacting within biologically-relevant multi-cellular contexts.

Atlante Seed initially invested in February 2014.